Altimmune (NASDAQ:ALT) Price Target Cut to $14.00 by Analysts at Citizens Jmp

Altimmune (NASDAQ:ALT) had its price objective decreased by Citizens Jmp from $15.00 to $14.00 in a research report released on Friday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

Several other research firms also recently commented on ALT. B. Riley dropped their price objective on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Wall Street Zen upgraded shares of Altimmune from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday, October 8th. JMP Securities lowered their target price on shares of Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a report on Thursday, July 10th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Monday, October 20th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Altimmune presently has a consensus rating of “Hold” and an average price target of $16.83.

Altimmune Stock Performance

Shares of Altimmune stock traded up $0.17 on Friday, reaching $4.11. 4,196,187 shares of the company traded hands, compared to its average volume of 3,502,033. The company has a 50 day moving average of $3.87 and a 200 day moving average of $4.54. The company has a debt-to-equity ratio of 0.09, a current ratio of 20.44 and a quick ratio of 20.44. Altimmune has a 52 week low of $2.90 and a 52 week high of $11.16. The firm has a market capitalization of $362.74 million, a PE ratio of -3.48 and a beta of 0.01.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Equities analysts forecast that Altimmune will post -1.35 earnings per share for the current year.

Institutional Trading of Altimmune

Large investors have recently modified their holdings of the business. Geneos Wealth Management Inc. purchased a new position in shares of Altimmune during the first quarter worth about $50,000. BNP Paribas Financial Markets grew its stake in Altimmune by 108.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after buying an additional 5,253 shares in the last quarter. Headland Capital LLC purchased a new position in Altimmune in the 1st quarter worth approximately $50,000. Kingswood Wealth Advisors LLC bought a new position in shares of Altimmune in the 2nd quarter worth $40,000. Finally, Prudential Financial Inc. purchased a new stake in shares of Altimmune during the 2nd quarter valued at $43,000. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.